Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 4
1995 4
1996 5
1997 17
1998 32
1999 57
2000 79
2001 90
2002 84
2003 96
2004 95
2005 63
2006 69
2007 42
2008 46
2009 63
2010 61
2011 52
2012 54
2013 51
2014 52
2015 32
2016 32
2017 25
2018 24
2019 33
2020 19
2021 37
2022 30
2023 28
2024 23
2025 28
2026 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,352 results

Results by year

Filters applied: . Clear all
Page 1
Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.
Adeoye O, Broderick J, Derdeyn CP, Grotta JC, Barsan W, Bentho O, Berry S, Concha M, Davis I, Demel S, Elm J, Gentile N, Graves T, Hoffman M, Huang J, Ingles J, Janis S, Jasne AS, Khatri P, Levine SR, Majjhoo A, Panagos P, Pancioli A, Pizzella S, Ranasinghe T, Sabagha N, Sivakumar S, Streib C, Vagal A, Wilson A, Wintermark M, Yoo AJ, Barreto AD. Adeoye O, et al. N Engl J Med. 2024 Sep 5;391(9):810-820. doi: 10.1056/NEJMoa2314779. N Engl J Med. 2024. PMID: 39231343 Free PMC article. Clinical Trial.
At 90 days, the mean ( SD) utility-weighted modified Rankin scale scores were 5.2 3.7 with argatroban, 6.3 3.2 with eptifibatide, and 6.8 3.0 with placebo. The posterior probability that argatroban was better than placebo was 0.002 (posterior mean difference in utility-wei …
At 90 days, the mean ( SD) utility-weighted modified Rankin scale scores were 5.2 3.7 with argatroban, 6.3 3.2 with eptifibatide, and …
[Eptifibatide (Integrilin)].
Holmvang L, Grande P. Holmvang L, et al. Ugeskr Laeger. 2001 Jan 22;163(4):468-72. Ugeskr Laeger. 2001. PMID: 11218791 Danish.
Eptifibatide (Integrilin) is a specific blocker of the glycoprotein IIb/IIIa receptor and an effective inhibitor of platelet aggregation. ...The present summary discusses the indications for the use of eptifibatide/Integrilin based on recent clinical t …
Eptifibatide (Integrilin) is a specific blocker of the glycoprotein IIb/IIIa receptor and an effective inhibitor of platelet a …
Delayed-onset eptifibatide-induced thrombocytopenia.
Huffman T, Gleaves E, Lenoir G, Rafeedheen R. Huffman T, et al. Am J Health Syst Pharm. 2024 Feb 8;81(4):106-111. doi: 10.1093/ajhp/zxad271. Am J Health Syst Pharm. 2024. PMID: 37884759
An eptifibatide platelet antibody assay was positive for IgG-mediated reactions consistent with eptifibatide-induced thrombocytopenia. Scoring of this case with the Naranjo scale yielded a score of 4, suggesting a possible adverse reaction to eptifibatide. CO …
An eptifibatide platelet antibody assay was positive for IgG-mediated reactions consistent with eptifibatide-induced thrombocy …
Eptifibatide overdose.
Parakh S, Naik N, Rohatgi N, Bhat U, Parakh K. Parakh S, et al. Int J Cardiol. 2009 Jan 24;131(3):430-2. doi: 10.1016/j.ijcard.2007.07.132. Epub 2007 Nov 19. Int J Cardiol. 2009. PMID: 18023892 Review.
Eptifibatide clearance is delayed in renal failure and in one report hemodialysis normalized hemostasis. ...Desmopressin reversed platelet dysfunction caused by eptifibatide in healthy volunteers but is untested in patients. CONCLUSION: Available data suggest that …
Eptifibatide clearance is delayed in renal failure and in one report hemodialysis normalized hemostasis. ...Desmopressin reversed pla …
Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.
Roy A, Elm J, Ingles JR, Sabagha N, Huang JF, Bentho O, Ranasinghe T, Streib C, Concha M, Khatri P, Vagal A, Wintermark M, Derdeyn CP, Broderick JP, Barreto AD, Adeoye O, Grotta JC. Roy A, et al. Neurology. 2025 Nov 11;105(9):e214228. doi: 10.1212/WNL.0000000000214228. Epub 2025 Oct 10. Neurology. 2025. PMID: 41071964 Clinical Trial.
There was only a 1% or 2.5% chance that argatroban or eptifibatide, respectively, was superior to placebo for the primary outcome (mean uwmRS scores [SD] of 5.5 [3.6], 6.6 [3.2], and 7.4 [2.6] for argatroban, eptifibatide, and placebo, respectively). ...The risk dif …
There was only a 1% or 2.5% chance that argatroban or eptifibatide, respectively, was superior to placebo for the primary outcome (me …
Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
Harrington RA. Harrington RA. Am J Cardiol. 1997 Aug 18;80(4A):34B-38B. doi: 10.1016/s0002-9149(97)00575-4. Am J Cardiol. 1997. PMID: 9291244 Review.
Earlier studies of the reversible peptide inhibitor of the GP IIb-IIIa receptor, eptifibatide (INTEGRILIN), in patients with unstable angina have demonstrated its potential in reducing acute ischemic events. The Platelet Glycoprotein IIb-IIIa in Unstable Angina: Rec …
Earlier studies of the reversible peptide inhibitor of the GP IIb-IIIa receptor, eptifibatide (INTEGRILIN), in patients with u …
Bleeding risk associated with eptifibatide (Integrilin) bridging in thoracic surgery patients.
Waldron NH, Dallas T, Erhunmwunsee L, Wang TY, Berry MF, Welsby IJ. Waldron NH, et al. J Thromb Thrombolysis. 2017 Feb;43(2):194-202. doi: 10.1007/s11239-016-1441-5. J Thromb Thrombolysis. 2017. PMID: 27798792 Free PMC article.
We sought to determine whether perioperative bridging with eptifibatide increased bleeding associated with thoracic surgery. After Institutional Review Board approval, we identified thoracic surgery patients receiving eptifibatide at our institution (n = 30). ...Whi …
We sought to determine whether perioperative bridging with eptifibatide increased bleeding associated with thoracic surgery. After In …
Development of eptifibatide.
Scarborough RM. Scarborough RM. Am Heart J. 1999 Dec;138(6 Pt 1):1093-104. doi: 10.1016/s0002-8703(99)70075-x. Am Heart J. 1999. PMID: 10577440 Review.
CONCLUSIONS: In clinical trials, culminating in the phase III IMPACT II (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) and PURSUIT (Platelet GP IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) trials, eptifibatide …
CONCLUSIONS: In clinical trials, culminating in the phase III IMPACT II (Integrilin to Minimize Platelet Aggregation and Coronary Thr …
Clinical pharmacology of eptifibatide.
Phillips DR, Scarborough RM. Phillips DR, et al. Am J Cardiol. 1997 Aug 18;80(4A):11B-20B. doi: 10.1016/s0002-9149(97)00572-9. Am J Cardiol. 1997. PMID: 9291241 Review.
In clinical trials, eptifibatide has not been found to be immunogenic or to induce thrombocytopenia. These studies have led to the evaluation of eptifibatide in the pivotal Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis (IMPACT II) trial, …
In clinical trials, eptifibatide has not been found to be immunogenic or to induce thrombocytopenia. These studies have led to the ev …
[GPIIb-IIIa inhibitors].
Nurden P. Nurden P. Transfus Clin Biol. 2001 Apr;8(2):114-22. doi: 10.1016/s1246-7820(01)00100-8. Transfus Clin Biol. 2001. PMID: 11386043 Review. French.
Two classes of products have been used in clinic, the chimeric monoclonal antibody Fab fragment, c7E3 or abciximab (ReoPro), which has been the pioneer, and synthetic peptides or peptidomimetics such as eptifibatide (Integrilin) or tirofiban (Agrastat). Abciximab is …
Two classes of products have been used in clinic, the chimeric monoclonal antibody Fab fragment, c7E3 or abciximab (ReoPro), which has been …
1,352 results